D
espite advances in asthma therapy and worldwide distribution of asthma guidelines, a significant number of patients with asthma continue to experience poor control of their disease. This recalcitrant form of asthma is commonly referred to as severe or difficult-to-treat asthma and is characterized by corticosteroid insensitivity, with persistent lack of control despite corticosteroid therapy or worsening of asthma control on reduction or discontinuation of corticosteroid therapy. While poor asthma control is frequently attributed to poor adherence to prescribed medications and/or recommended environmental restrictions, 5 -10% of patients experience poor control because they suffer from an underlying severe asthma pathophysiology characterized by airway inflammation resistant to medical therapy. 1 Although the population of patients with severe asthma is relatively small, this group deserves special focus because they account for a substantial portion of total asthma morbidity, mortality and cost. Until recently, few clinical studies were specifically designed to investigate the many other facets of treatment failure of patients with severe asthma, that include inhaler technique or which offer newer forms of treatment such as thermoplasty. In this context, the majority of the nine asthma-related articles within this issue directly or indirectly relate to the severe asthma phenotype and focus on these unexplored areas.
In addition to poor therapeutic adherence, poor asthma control may be significantly impacted by inadequate inhaler technique. To study this issue further, The Asthma and Allergy Foundation of America collected data from 590 questionnaire respondents. In their analysis of this data, Storms et al report that unnecessary health care utilization and avoidable loss of time at work or school were associated with the limited availability of properly functioning quick-relief inhalers. 2 They further observed that confidence around proper inhaler use was low and that adding a dose counter may improve satisfaction with quick-relief inhalers.
Among other emerging treatments, bronchial thermoplasty is the only nonpharmacologic intervention approved by the United States Food and Drug Administration in 2010, available as a new treatment option for the patient with severe asthma. In the interest of assisting the allergist-immunologist in the decisionmaking process for the use of this new treatment modality, two separate articles by Dunn/Wechsler 3 and
Iyler/Lim 4 are presented in this issue of the Proceedings offering opposing viewpoints on the role of bronchial thermoplasty in a pro/con debate format. In addition, employing a novel publication format, each author was given an opportunity to make rebuttal comments to each other's presentation which are published in the accompanying editorial. 5 It is hoped that this information will help empower the allergist-immunologist to make the best treatment decisions for the patient with severe asthma.
Patients with severe asthma require repeated oral corticosteroid treatment, which is frequently associated with a variety of drug-related adverse events. Zazzali et al attempt to better characterize this risk through an analysis of data derived from a commercial health care claims database, matching 3,604 asthma patients who were high-oral corticosteroid (OCS) users to 3,604 no-OCS users. 6 They report that asthma patients treated with OCS for Ն30 days per year have a greater overall risk of possible corticosteroid-related AEs compared to those with no OCS use.
In the search for predictive markers of corticosteroid mechanisms of action, Bhargava et al evaluated the effect of systemic corticosteroids on serum levels of apoptotic markers surviving (for inflammatory cells) and M30 apoptosense (for bronchial epithelial cells) in 60 patients experiencing acute exacerbation of bronchial asthma. 7 Their results suggest that systemic corticosteroids administration decreases the survival of inflammatory cells and increases that of bronchial epithelial cells in patients with acute exacerbation of bronchial asthma.
For patients with more severe asthma who require frequent use of systemic corticosteroids, current asthma guidelines emphasize achieving and maintaining asthma control by stepping up therapy as required. More specifically, steps 5 and 6 of the Expert Panel Report 3 recommend consideration of omalizumab. 8 In an effort to provide real-world evidence to assist in clinical decision making, Zazzali et al set out to describe longitudinal changes of asthma control for patients with moderate-to-severe asthma treated with omalizumab in comparison to those not receiving omalizumab. 9 To accomplish this, the authors analyzed 5-year data from patients aged Ն12 years with moderate-to-severe persistent allergic asthma enrolled in the Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-severe Asthma (EXCELS) observa-tional study. 10 The authors conclude that patients in EXCELS who initiated omalizumab experienced clinically significant improvement in asthma control that was observed within 6 months and persisted for 5 years.
In addition to stepping up therapy as required, asthma guidelines also emphasize stepping down therapy when appropriate. Despite this guidance, however, current protocols for stepping down therapy remain inadequately studied. 11 In this context, Gionfriddo et al performed a systemic review and meta-analysis on the topic of stepping down from scheduled to asneeded inhaled corticosteroids. 12 The authors conclude that there is currently insufficient evidence to associate stepping down with a change in the exacerbation rate.
With regard to asthma exacerbations in children, two articles appear within the pages of this issue that provide novel information regarding biomarkers of disease activity. Chen et al present data which suggests that B7-H3 (a recently identified member of the B7 family) may be a clinically useful biomarker to evaluate asthma exacerbations in children. 13 Continuing the search for biomarkers in asthma, Ma et al report that urinary CC16 may be a useful biomarker for investigating lung epithelium integrity in children with asthma.
14 Supplementing this novel research on asthma biomarkers, this issue also presents information regarding asthma risk factors and associations related to age (children and young adults) and sex (females). Arikoglu et al present results which demonstrate that both vitamin D deficiency and cathelicidin levels show a significant and independent positive association with acute asthma attacks in allergic children. 15 Stelmach et al present research which suggests that exposure to phthalates is a risk factor for wheezing and food allergy in children. 16 In a young adult Japanese population, Kimura et al assessed the epidemiology of asthma and allergic rhinitis by questionnaire, and report contrasting associations of high BMI and past measles infection with asthma and allergic rhinitis. 17 Because of its significant clinical implications the article by Kimura and colleagues was chosen for this issue's "For the Patient" section (a one page synopsis of a selected article, written in a readily comprehensible fashion to help educate patients).
In addition to asthma risk factors and associations related to age, this issue features a review article by Frieri which addresses differences between the sexes with regard to factors which contribute to poor asthma control including the presence of anxiety, depression, and the role of hormones and stress in women. 18 As a reflection of the diversity found within this issue, also included are articles which relate to risk of allergic sensitization, treatment of allergic rhinitis, biomarkers of atopic dermatitis, and survey data regarding anaphylactic events in schools. The research findings of Lee et al demonstrate a novel interplay of low solar irradiation and risk of sensitization to dust mite. 19 In a head to head, 2-week treatment study during the fall ragweed season, Ford et al compare fluticasone propionate nasal spray to oral cetirizine and to placebo and report finding equal efficacy of both medications. 20 Tsybikov et al report that in patients with atopic dermatitis, plasma endothelin-1 (ET-1) levels are elevated and are positively correlated with clinical severity, itch intensity and serum IgE levels. 21 White et al performed a cross-sectional, web-based survey of 6,019 schools participating in the EpiPen4Schools program which assessed anaphylactic events and epinephrine autoinjector (EAI) use during the 2013-2014 school year. 22 They found that greater than one in ten schools participating in the EpiPen4Schools survey reported an anaphylactic event. Of concern, ϳ25% of anaphylactic events were not treated with EAIs, and 20.4% of patients were not taken to the hospital after an anaphylactic event. The authors conclude that their data support the value of stocking EAIs in schools and providing continuing education regarding the recognition and proper treatment of anaphylaxis for school personnel.
In summary, the collection of articles found within the pages of this issue provides yet another insight into important allergic, cutaneous and respiratory disorders afflicting patients whom the allergist-immunologist serves. In keeping with the overall mission of the Proceedings, which is to distribute timely information regarding advancements in the knowledge and practice of allergy, asthma, and immunology to clinicians entrusted with the care of patients, it is our hope that the articles found within this issue will continue to achieve this goal and will help foster enhanced patient management through efficient workup and optimal therapy for a great variety of clinical problems. On behalf of the editorial board, we hope you will enjoy the diversity of literature offered in this issue of the Proceedings. 
